Key result
Elevated log-transformed urinary N-acetyl-β-D-glucosaminidase levels were significantly associated with the presence of cardiovascular autonomic neuropathy (OR 2.39) in patients with type 1 diabetes without nephropathy.
Why the study?
Cardiovascular autonomic neuropathy is linked to diabetic nephropathy, and urinary N-acetyl-β-D-glucosaminidase is an early marker of nephropathy even with normoalbuminuria, but its association with cardiovascular autonomic neuropathy in type 1 diabetes without nephropathy was unclear.
Is urinary N-acetyl-β-D-glucosaminidase (uNAG) associated with the presence and severity of cardiovascular autonomic neuropathy in patients with type 1 diabetes mellitus without nephropathy?
Cross-Sectional (n=247)
No
Is urinary N-acetyl-β-D-glucosaminidase (uNAG) associated with the presence and severity of cardiovascular autonomic neuropathy in patients with type 1 diabetes mellitus without nephropathy?
Odds Ratio: 2.39 (95% CI 1.08–5.28)
p-value: p=0.031
Urinary NAG levels are associated with the presence and severity of cardiovascular autonomic neuropathy in patients with type 1 diabetes without nephropathy, suggesting its potential as an early marker.
uNAG elevation may mark early CAN in T1D without nephropathy; hypothesis-generating from cross-sectional data, does not yet change practice.
BACKGROUND: Cardiovascular autonomic neuropathy (CAN) is a common microvascular complication of diabetes and related to albuminuria in diabetic nephropathy (DN). Urinary N-acetyl-β-D-glucosaminidase (uNAG) is a renal tubular injury marker which has been reported as an early marker of DN even in patients with normoalbuminuria. This study evaluated whether uNAG is associated with the presence and severity of CAN in patients with type 1 diabetes mellitus (T1DM) without nephropathy. METHODS: This cross-sectional study comprised 247 subjects with T1DM without chronic kidney disease and albuminuria who had results for both uNAG and autonomic function tests within 3 months. The presence of CAN was assessed by age-dependent reference values for four autonomic function tests. Total CAN score was assessed as the sum of the partial points of five cardiovascular reflex tests and was used to estimate the severity of CAN. The correlations between uNAG and heart rate variability (HRV) parameters were analyzed. RESULTS: The association between log-uNAG and presence of CAN was significant in a multivariate logistic regression model (adjusted odds ratio, 2.39; 95% confidence interval [CI], 1.08 to 5.28; P=0.031). Total CAN score was positively associated with loguNAG (β=0.261, P=0.026) in the multivariate linear regression model. Log-uNAG was inversely correlated with frequency-domain and time-domain indices of HRV. CONCLUSION: This study verified the association of uNAG with presence and severity of CAN and changes in HRV in T1DM patients without nephropathy. The potential role of uNAG should be further assessed for high-risk patients for CAN in T1DM patients without nephropathy.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2021) conducted a cross-sectional in Type 1 Diabetes Mellitus without Nephropathy (n=247). Urinary N-acetyl-β-D-glucosaminidase (uNAG) was evaluated on Presence of cardiovascular autonomic neuropathy (CAN) (OR 2.39, 95% CI 1.08-5.28, p=0.031). Elevated log-transformed urinary N-acetyl-β-D-glucosaminidase levels were significantly associated with the presence of cardiovascular autonomic neuropathy (OR 2.39) in patients with type 1 diabetes without nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: